Klas Wiman

Klas Wiman

Professor | Docent
Visiting address: BioClinicum, J6:10, Akademiska stråket 1, 17164 Solna
Postal address: K7 Onkologi-Patologi, K7 Forskning Wiman, 171 77 Stockholm

About me

  • I am Professor of Molecular Cell and Tumor Biology at Karolinska Institutet since 1999. My main research interest is cancer and novel cancer therapy. For more than three decades, I have studied the tumor suppressor gene TP53. I was coordinator of an EU Integrated project (Mutp53) with 23 partners and a budget of 8 M Euros 2004-2009, and have co-edited two books on p53 (Springer 2005 and 2012). I have also co-founded the company Aprea Therapeutics with colleagues with the aim of developing novel p53-targeted anti-cancer drugs. More recently, my research has been supported by an ERC Advanced Grant.


  • My laboratory performs research on p53 and the p53 tumor suppressor pathway, the p53 target gene Zmat3 (Wig-1), and therapeutic reactivation of mutant p53. We have identified the molecule APR-246 that can trigger apoptosis in TP53 mutant tumor cells and inhibit tumor growth in vivo in mice. It targets the cellular redox balance as well. APR-246 has been tested in several clinical trials in patients with MDS/AML. We are exploring the use of APR-246 for cancer prevention. We are also working on novel strategies for pharmacological induction of translational readthrough for reactivation of nonsense mutant TP53 in tumors.

Selected publications


All other publications


  • Professor, Department of Oncology-Pathology, Karolinska Institutet, 1999-

Degrees and Education

  • Docent, Karolinska Institutet, 1987

News from KI

Events from KI